At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LRMR Larimar Therapeutics, Inc.
Post-Mkt 03-18 17:40:59 EDT
4.30
-0.08
-1.83%
盘后4.32
+0.02+0.47%
17:16 EDT
High4.41Low4.24Vol1.12M
Open4.40D1 Closing4.38Amplitude3.77%
Mkt Cap447.20MTradable Cap316.74MTotal Shares104.00M
T/O4.83MT/O Rate1.52%Tradable Shares73.66M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

James E. Flynn, Director, Acquires Larimar Therapeutics Common Shares
Reuters  ·  03-03
James E. Flynn, Director, Acquires Larimar Therapeutics Common Shares
Larimar Therapeutics Director Jeffrey W. Sherman Acquires Common Shares
Reuters  ·  03-03
Larimar Therapeutics Director Jeffrey W. Sherman Acquires Common Shares
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Larimar Therapeutics (LRMR)
TIPRANKS  ·  02-28
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Larimar Therapeutics (LRMR)
Top Premarket Decliners
MT Newswires Live  ·  02-26
Top Premarket Decliners
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
THOMSON REUTERS  ·  02-26
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
Larimar Therapeutics Inc - Prices Upsized Public Offering at $5.00 per Share
THOMSON REUTERS  ·  02-26
Larimar Therapeutics Inc - Prices Upsized Public Offering at $5.00 per Share
BUZZ-Larimar Therapeutics slips after $75 mln stock offering commenced
Reuters  ·  02-26
BUZZ-Larimar Therapeutics slips after $75 mln stock offering commenced
Press Release: Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
Dow Jones  ·  02-26
Press Release: Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
Laminar Therapeutics Stock Is Popping Today: What's Going On?
Benzinga_recent_news  ·  02-26
Laminar Therapeutics Stock Is Popping Today: What's Going On?
Larimar Therapeutics Up Over 64%, on Pace for Largest Percent Increase Since January 2016 -- Data Talk
Dow Jones  ·  02-26
Larimar Therapeutics Up Over 64%, on Pace for Largest Percent Increase Since January 2016 -- Data Talk
NASD Most Active Issues
Dow Jones  ·  02-25
NASD Most Active Issues
Larimar Therapeutics Up Nearly 32%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk
Dow Jones  ·  02-25
Larimar Therapeutics Up Nearly 32%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk
BUZZ-U.S. STOCKS ON THE MOVE-Henry Schein, Domino's Pizza, FactSet
Reuters  ·  02-24
BUZZ-U.S. STOCKS ON THE MOVE-Henry Schein, Domino's Pizza, FactSet
BUZZ-U.S. STOCKS ON THE MOVE-Advanced Micro Devices, Constellation Energy, NRG Energy
Reuters  ·  02-24
BUZZ-U.S. STOCKS ON THE MOVE-Advanced Micro Devices, Constellation Energy, NRG Energy
Larimar Therapeutics Shares up 35.6% Premarket on FDA's 'Breakthrough' Tag for Neurological Disorder Therapy
THOMSON REUTERS  ·  02-24
Larimar Therapeutics Shares up 35.6% Premarket on FDA's 'Breakthrough' Tag for Neurological Disorder Therapy
BUZZ-Larimar jumps on FDA's 'breakthrough' tag for neurological disorder therapy
Reuters  ·  02-24
BUZZ-Larimar jumps on FDA's 'breakthrough' tag for neurological disorder therapy
Larimar Shares Jump Premarket on Breakthrough Therapy Designation for Lead Compound
Dow Jones  ·  02-24
Larimar Shares Jump Premarket on Breakthrough Therapy Designation for Lead Compound
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation For Nomlabofusp
Reuters  ·  02-24
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation For Nomlabofusp
FDA grants Breakthrough Therapy Designation to Larimar’s nomlabofusp for Friedreich’s ataxia
Reuters  ·  02-24
FDA grants Breakthrough Therapy Designation to Larimar’s nomlabofusp for Friedreich’s ataxia
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in Fa and Reiterates Planned Bla Submission in June 2026
THOMSON REUTERS  ·  02-24
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in Fa and Reiterates Planned Bla Submission in June 2026

Introduction

Company Name.
Larimar Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
Issue price:
--